FOCUS ON CHRONIC NEURODEGENERATION

CLINICAL-TRANSLATIONAL RESEARCH SYMPOSIUM

PLATFORM PRESENTATIONS

PERK Inhibition in rTg4510 mouse model of tauopathy rescues impairment through eIF2α-independent pathway

Shelby Meier¹ • Danielle Lyons, PhD² • Alex Ingram 2 • Jennifer Rodriguez-Rivera, PhD² • Dave Powell, PhD² • Moriel Vandsburger, PhD² • Joe Abisambra, PhD²

¹Physiology, University of Kentucky • ²Physiology, University of Kentucky

maintaining homeostasis during conditions of endoplasmic re- blot analysis, and other targets of the PERK pathway were ticulum (ER) stress. However, prolonged UPR activity causes measured using immunohistochemistry and real-time PCR. cellular dysfunction and death. Chronic activation of the Protein Kinase R-like ER Kinase (PERK) pathway of the UPR has been documented in many tauopathies; however, the mechanism by which the PERK pathway causes neuronal dysfunction in these diseases remains unknown.

Hypothesis: Tau mediates neuronal dysfunction through the improvements via an eIF2 α -independent mechanism. Our re-PERK pathway, and inhibition of this pathway rescues impairment observed in the rTg4510 mice.

Methods: rTg4510 tau transgenic mice were treated with a PERK inhibitor (GSK2606414) at 50mg/kg twice daily. Neuronal function was measured using manganese-enhanced magnetic resonance imaging (MEMRI) with quantitative R1 mapping, the anxiety phenotype was measured using the open field behavior-

Background: The unfolded protein response (UPR) is vital for al test, tau and active PERK levels were measured using western

Results and Conclusions: Here we show that treatment led to improvement of neuronal function measured by MEMRI, reversed the anxiety phenotype observed in the rTg4510 model, and resulted in a significant reduction in hyperphosphorylated tau levels. We also found that PERK inhibition mediated these sults show a novel mechanism of PERK-mediated tau phosphorylation that potentiates pathogenesis and progression of tau pathology. This study suggests that PERK is a viable therapeutic target to ameliorate neuronal function in tauopathies. Future efforts aim to delineate the mechanism governing the tau- PERK relationship.